Assessment of a patient after hospital-treated self-harm or psychiatric hospitalization often includes a risk assessment, resulting in a classification of high risk versus low risk for a future episode of self-harm. Through systematic review and a series of meta-analyses looking at unassisted clinician risk classification (eight studies; N = 22,499), we found pooled estimates for sensitivity 0.31 (95% CI: 0.18-0.50), specificity 0.85 (0.75-0.92), positive predictive value 0.22 (0.21-0.23), and negative predictive value 0.89 (0.86-0.92). Clinician classification was too inaccurate to be clinically useful. After-care should therefore be allocated on the basis of a needs rather than risk assessment.
12 months, with one third of these episodes occurring in the month after discharge (Gunnell et al., 2008) .
Even in these two high-risk clinical populations (hospital-treated self-harm and discharged psychiatric inpatients), suicide is uncommon in absolute terms, and it has been recognized for more than 60 years that low-frequency disorders like suicide are impossible to predict with a clinically useful positive predictive value (PPV). This is because the very low prevalence of suicide imposes a ceiling on the PPV (Rosen, 1954) , and this ceiling is independent of the predictive method used (Carter et al., 2017) . In the general hospital and the psychiatric hospital setting, a typical goal is to distinguish between patients at high and low risk for suicide in order to allocate after-care, although this approach has been criticized: "it is simply not possible to predict suicide in an individual patient, and any attempt to subdivide patients into high-risk and lowrisk categories is at best unhelpful and at worst will prevent provision of useful and needed psychiatric care" (Ryan & Large, 2013) . A recent systematic review of 53 risk assessments from 37 studies demonstrated this more precisely, finding the pooled estimates for sensitivity (56%) and PPV (5.5%) for the classification of high risk of future suicide . A second systematic review estimated a pooled PPV (5.5%; Carter et al., 2017) and a third review reported a range of PPV (1.3%-16.7%; Chan et al., 2016) for a high risk of suicide classification. There have been seven recent systematic reviews that when considered collectively have demonstrated that any individual risk factor, instrument, or scale used to classify patients into a high-risk group for later suicide may do so modestly better than chance; however, around half of all suicides come from the low-risk classification, while very few of the patients in the high-risk classification die by suicide Chan et al., 2016; Chapman et al., 2015; Franklin et al., 2017; Hubers et al., 2016; Ribeiro et al., 2016) . None of these systematic reviews included studies of unassisted clinician prediction.
However, as self-harm in clinical populations is much more common than suicide, the question arises: "Can clinicians predict future self-harm with sufficient accuracy to be clinically useful?"
The state of clinical risk assessment in current practice for hospital-treated selfharm is difficult to know. In the UK, there have been standards established for the assessment and care of self-harm patients by the Royal College of Psychiatrists (Royal College of Psychiatrists, 2010) and by clinical practice guidelines published by the National Institute for Health and Care Excellence (NICE; National Institute for Health and Care Excellence, 2011), which suggest that any form of risk assessment to establish a high-risk classification of patients, by clinician or validated instruments, in order to allocate treatment is not useful. However, "Evidence also exists of widespread failure by NHS services to comply with the NICE Guideline on Self Harm" (Royal College of Psychiatrists, 2010) . A stratified sample of 32 UK hospitals found that risk classification was still being done; most commonly using "unvalidated locally developed proformas" (41% of EDs and 69% of mental health services) in the prediction of future self-harm, with others using a variety of standardized scales, clinician judgment, or some combination of methods (Quinlivan et al., 2014) . In other parts of the world, there may be greater reliance on clinician judgment as the usual method for determining risk of suicide or self-harm.
Unassisted (or partly assisted) clinical judgment is a form of risk assessment whereby clinicians stratify patients into various risk groupings (most commonly high vs. low risk), and there are current recommendations from the United States that favor the use of a clinician risk assessment to classify patients into risk groups (high vs. low) in order to allocate treatment: (1) "The main procedure used by clinicians to determine whether an individual may be at (SPRC, 2015) . The aim of the current systematic review and meta-analysis was to quantify the accuracy of unstructured clinician assessments of future risk of self-harm in hospital-treated clinical populations with relatively high rates of subsequent selfharm. We calculated estimates of the key accuracy statistics for this task, especially the positive (PPV) and negative predictive values (NPV). An understanding of the absolute degree of accuracy (or inaccuracy) of clinician judgment to determine risk stratification will inform us about the usefulness of clinician prediction when positive (e.g., for the allocation of clinical after-care to prevent future self-harm events) and when negative (e.g., regarding the safe to discharge home decision).
METHODOLOGY
This study was prospectively registered on the PROSPERO database with registration number 2015:CRD42015015 781. We used the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA; Liberati et al., 2009) to report the identified studies and the metaanalyses and QUADAS rating system to assess risk of bias in diagnostic accuracy studies (Whiting et al., 2011) .
Searches were conducted of medical and scientific databases, including Medline, PsychInfo, EMBASE, CINHAL, Web of Science, and Scopus, inclusive of all papers from database inception until January 2016. A secondary search of the papers identified in another systematic review regarding the accuracy of standardized and validated predictive instruments was also undertaken to identify any incidental clinician predictions (Carter et al., 2017) . Further papers were obtained by searching the reference lists of each paper retrieved; use of the "find similar" functions for seminal papers in PubMed and Web of Science; and screening the reference lists of books dealing with the topic of clinician judgment. A search of the grey literature was conducted in January 2016 with review of the first 100 sources identified by the search engines Google and Google Scholar through combinations of the keywords.
Key terms used for the search included "self-harm" OR "suicide*," together with their suggested synonyms, and "predict*" OR "forecast" AND "clinician" OR "clinical judgement" OR "clinical decision making."
Inclusion and Exclusion Criteria
Eligible studies included those with original data on clinician prediction of future self-harm, or suicide attempt. These were required to be cohort studies of at least 10 participants and include outcomes after any follow-up period. Study populations could include any nonpediatric population (≥ 12 years), with treatment settings including psychiatric hospital inpatients for any reason, and ED presentations or general hospital admissions for self-harm. Any studies reporting subgroups of these populations were included, and data were pooled from studies that separated estimates on a basis of gender. Any studies that used "locally developed structured proformas" or validated instruments to determine risk assessment were excluded. Only studies published in English were included. Titles and abstracts recovered in the search were screened for study suitability, and full-text copies of papers were retrieved that possibly dealt with the review topic. Duplicated papers were removed at this point.
The retrieved papers were screened independently by two different reviewers (RW, GLC) and excluded or included on the basis of the aforementioned criteria. Final papers included a quantified assessment of clinician risk (high/medium/low) or (high/low).
Study Characteristics
Key study characteristics were extracted from the selected papers and presented in tabular form as follows: author, year, clinical setting, country, clinician rater, gender of population, and risk stratification.
Data Extraction for Accuracy Statistics
Data from the final studies were pooled into high versus low risk as judged by clinicians. In papers that compared the rating accuracy of a number of clinician groups, additional sets of data were extracted for each clinician group. If a "medium or moderate" risk judgment was made, this was combined with the "low" assessment of risk to obtain two groups (high vs. low risk) in order to achieve the combination most consistent with the proportions (high vs. low risk) used in studies that only reported a two-level classification of risk stratification. One study had combined the "moderate" with the "high" risk group for reporting (Cooper, Kapur, & Mackway-Jones, 2007) ; one study had combined the "moderate" with "low" risk group for reporting (Kapur et al., 2005) ; and one study had an additional stratification of "high" and "very high" (Phillips, Stargatt, & Brown, 2012 ), which we combined into "high" risk for all analyses. Data were extracted from the studies directly into a 2 9 2 table, and any missing values were calculated from the data available.
Statistical Analyses
Accuracy statistics, sensitivity, specificity, PPV, NPV, and clinical utility as determined by likelihood ratio positive (LR+) and likelihood ratio negative (LRÀ) for self-harm outcomes for each individual study were calculated from the 2 9 2 tables using an online calculator, Diagnostic and AGreement Statistics (DAGStat; http:// www.biostats.com.au/DAG_Stat/#Top). A LR+ score in the range of 5-10 was considered to be a moderate increase in the likelihood of the predicted outcome, while a LRÀ score in the range of 0.1-0.2 was considered to be a moderate decrease in the likelihood of the predicted outcome and hence potentially clinically useful. For each clinician prediction, we also calculated the clinical utility of a positive (CUI+; positive = high risk) or negative (CUIÀ; negative = low risk) decision (see www. clinicalutility.co.uk) (Mitchell, 2011) . CUI scores were considered in qualitative grades: excellent ≥ 0.81, good 0.80-0.64, satisfactory 0.63-0.49, and poor utility < 0.49 (Mitchell, 2011) .
We calculated pooled estimates of sensitivity, specificity, PPV, and NPV. The general form of our models was to estimate either the pooled sensitivity or specificity jointly (or the pooled PPV and the NPV jointly) using the binomial-normal model (Stijnen, Hamza, & Ozdemir, 2010) . This is a random effects logistic regression model with an unstructured covariance matrix to allow a correlation between the study-
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CLINICIAN PREDICTION OF SELF-HARM specific estimates of sensitivity and specificity (or PPV and NPV). We estimated the pooled parameters on the logit scale and back-transformed them to proportions for presentation. Of the studies we examined, all but one followed individuals over time.
The remaining study counted episodes (Cooper et al., 2007) , not persons, and as such, we conducted a secondary analysis excluding this study from the pooled results. Heterogeneity was assessed through visual inspection of the forest plots and with the I 2 statistic, which provides an estimate of inconsistency across studies. The metaanalyses of diagnostic values differ from the meta-analyses of intervention studies in several key ways. First, heterogeneity is to be expected; second, random effects models are used to estimate this heterogeneity (Macaskill, Gatsonis, Deek, Harbord, & Takwoingi, 2010) ; and third, the I 2 statistic overestimates heterogeneity in metaanalyses of diagnostic or predictive tests (Bossuyt et al., 2013) . Publication bias was assessed using a modified version of Egger's test (Egger, Smith, Schneider, & Minder, 1997) , which uses linear regression but is based on the efficient score and its variance (Harbord, Egger, & Sterne, 2006) .
Risk of Bias Rating
Each clinician evaluation was rated independently by two reviewers (RW, GLC) for risk of bias using an adapted form of the QUADAS-2 (QUality Assessment of Diagnostic Accuracy Studiesversion 2) rating instrument (Whiting et al., 2011) . This tool assessed risk of bias in four domains: patient selection (two items: participant selection [random or consecutive] and exclusions less than 15% of population), index test (one item: blinding to outcome), reference standard (two items: classification of outcomes and blindness of rating), and flow and timing (three items: duration of follow-up 1 year or less, same outcome measurement for all, dropout < 15%). For each of these rating points, the risk of bias was assessed as low, high, or unclear. Any discrepancies in quality assessment were discussed and resolved by the two reviewers.
RESULTS
The search yielded five peer-reviewed published papers (Cooper et al., 2007; Erdman, Greist, Gustafson, Taves, & Klein, 1987; Kapur et al., 2005; Murphy, Kapur, Webb, & Cooper, 2011; Phillips et al., 2012) and one thesis from the grey literature (Naydock, 2015) , which can be seen in the PRISMA diagram in Figure 1 , for a total of (eight clinician evaluations (Table 1) . Five evaluations were conducted in the ED of a general hospital, one in the ED of a veterans' hospital, one in an adult psychiatric hospital, and one in an adolescent psychiatric hospital. Five evaluations were made in UK populations, two in the United States, and one in Australia. A variety of clinicians conducted the assessments including mental health and ED staff. Seven evaluations predicted any individual having one or more future episodes with the unit of analysis as the individual, and one with the unit of analysis being events not individuals. Five evaluations used self-harm as the outcome, one used self-harm or suicide death, and two used suicide attempt. Follow-up duration was 12 months for the general hospital populations, 24 months for the veterans' hospital population, and 1 and 3 months for the psychiatric hospital populations. The range of the proportion of patients allocated to the high-risk category for seven evaluations was 7.6%-19.9%, and 65.8% for one evaluation that used events rather than individuals and combined medium and high to produce a high-risk group (Cooper et al., 2007) .
There were 22,499 predictions made: true positives (1,685), false positives (5,996), false negatives (1,556), and true negatives (13, 262) . The prevalence of the outcomes (repeat self-harm or suicide attempt) and the accuracy statistics for clinician prediction for each individual evaluation can be seen in Table 2 ; LRs and CUI values are shown in Table 3 . The 12-month prevalence for general hospital populations ranged from 13%-15% in the studies of individuals and was 17% in the evaluation using events. The prevalence in the psychiatric hospital populations was higher despite shorter follow-up, 21% (adult 3 month) and 17% (adolescent 1 month) and for the veterans' hospital lower despite longer follow-up, 7.1% (24 month). 
Secondary Analyses
A secondary analysis using only those studies where individuals (not events) were followed over time (k = 7) showed calculated estimates of PPV 0.22 (0.20-0.24) and NPV 0.89 (0.85-0.92). Full-text arƟcles assessed for eligibility (n = 77)
Full-text arƟcles excluded, with reasons (n = 71)
Design issues (e.g., case control study, incidence study, used hypotheƟcals)= 9
No extractable or relevant outcome data= 11
Did not use unassisted clinical judgement as a predictor= 32
Review or commentary= 17
Other (sample issues)= 2
Studies included in quanƟtaƟve synthesis (n = 6) Total records screened (aŌer duplicates removed) (n = 1724) Authors combined "medium" with "high" risk.
e Authors originally used a "high-" risk and "very high-" risk stratification.
f Authors combined "moderate" with "low" risk.
g Unit of analysis is events not individuals.
TABLE 2
Prevalence of Repeat Self-Harm and Accuracy Statistics for Clinician Classification for Future Self-Harm 
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Risk of Bias
The QUADAS risk of bias ratings showed that only three of eight studies had a low risk of bias for patient selection; however, there was a low risk of bias overall for the other three ratings (index test, reference standard, and flow and timing). Details of risk of bias ratings for each study can be seen in Table 4 , and indicators of possible publication bias can be seen in the funnel plots in Figures 4a and 4b .
The estimates of between-study heterogeneity for sensitivity and specificity were large (I 2 = 98% and 100%, respectively). The between-study heterogeneity for PPV was low (I 2 = 2%), but for NPV it was large (I 2 = 95%). As noted earlier, these values are somewhat misleading in the context of meta-analyses evaluating the diagnostic or predictive properties of an instrument.
DISCUSSION
Main Findings
The question of whether clinicians can predict future self-harm with sufficient accuracy to be clinically valuable is addressed by several results from our study. Sensitivity and specificity are useful accuracy statistics to understand how well a predictive test identifies cases and noncases within a clinical population. The pooled estimates for sensitivity (0.31) show that nearly 70% of all cases of future self-harm would be misclassified by clinicians as low risk, meaning that most future cases would not be allocated to receive after-care aimed at reducing future self-harm, based on this risk classification. The pooled estimates for specificity (0.86) show that although 86% of future noncases (i.e., no future self-harm event in the follow-up period) will be accurately classified as low risk, 14% of the noncases would therefore be misclassified as high risk (false positives) and allocated to after-care aimed at reducing future selfharm from which they would not benefit. These statistics are of more use at the public health level (e.g., to allocate resources needed for treatment at the hospital level) but are not able to accurately estimate the probability of future self-harm at the individual level, which is required by the clinician in order to make a binary judgment about allocation of after-care and safe to discharge home decisions.
There are several questions that can be used to guide decisions about the usefulness of a predictive test for the clinician. Can a high-risk classification be used to allocate after-care interventions for those that need it? The pooled PPV (0.22) shows 
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that only 22% of patients classified as high risk will experience the adverse outcome of interest (i.e., self-harm). Thus, allocation of relatively expensive after-care (psychosocial interventions) with demonstrated effectiveness for reducing future self-harm (Hetrick, Robinson, Spittal, & Carter, 2016) based on this classification will allocate 77% of the high-risk group to after-care that will be of limited or no benefit for the future selfharm outcome. Another approach is to use the LR+ (1.67), which shows that there is very little change from the pre-test probability (14.8%) to the post-test probability (23%). This would be considered to be a minimal improvement in prediction over the expected rate and not clinically useful.
A third approach is to use the CUI+ (0.11) (sensitivity 9 PPV), which would be considered to be poor utility for a diagnostic or predictive test (Mitchell, 2011) . These two additional tests of clinical utility reinforce the interpretation of the PPV result and indicate that a high-risk classification is not a useful basis for the allocation of psychosocial after-care interventions aimed at prevention of future self-harm. Clinicians can also use the classification as low risk by a risk assessment to answer the important clinical question: Is it safe to discharge this patient home? For this question, the clinician may reference the pooled NPV (0.89), which indicated that more than 1 in 10 patients classified as being low risk will have a future self-harm event, often soon after discharge (Carroll et al., 2014; Gunnell et al., 2008) . Hospitaltreated self-harm is a very common phenomena at the whole of population level and so this 10% misclassification as low risk means that many thousands of patients, at a national level, declared as safe for discharge will repeat self-harm, without the benefit of potentially effective after-care. Indeed, the LRÀ (0.70) indicates a small improvement from the pre-test probability (14.8%) to the post-test probability (11%). Similarly, the CUIÀ (0.62) (specificity 9 NPV) was considered to have only satisfactory utility because only 62% of noncases would fall into a low-risk categorization, despite this low-risk judgment being a true negative in 89% of all low-risk estimates. Although a nearly 90% accuracy in predicting future self-harm based on a negative test result might seem superficially reassuring, this is really only slightly different to the known probability of future self-harm in these populations before the clinician prediction is made (e.g., 86% with no repetition of hospital-treated self-harm after 12 months).
Confounding by Indication
There are an important set of questions to be considered when interpreting the PPV results (and if we ignore for this point the nearly 70% of repeat self-harm cases that were allocated to the low-risk classification).
Could the low PPV estimates be adversely affected because of confounding by indication (i.e., patients allocated to a high-risk category then received after-care that was effective at reducing the rate of repetition in the high-risk group)? If there was such confounding by indication, what might be the magnitude of such confounding (i.e., by how much would interventions reduce the subsequent repeat self-harm rate and would this substantially affect the interpretation of the outcomes of the study)?
First, all of the original studies seem to infer that risk assessment was part of usual clinical practice and so we must assume that the possibility of confounding by indication is real. Second, the allocation of after-care and the compliance of hospital-treated self-harm patients in attending allocated after-care interventions are generally poor. In a study of all Norwegian hospitals, which have a commitment to a codified high standard of care, 76% of hospitals met the standard for allocation of after-care (to 90% or more of all suicide attempt patients; Mehlum, Mork, Reinholdt, Fadum, & Rossow, 2010) . Historically, Kreitman (1979) reported that 50% of hospital-treated self-harm patients failed to attend any outpatient appointment, while O'Brien, Holton, Hurren, Watt, & Hassanyeh (1987) reported 60% noncompliance at 1 week and 69% nonattendance after 4 weeks for allocated outpatient treatment. Even in more recent times and with assertive outreach to a highly selected sample, for those offered after-care, only 73% attended one or more sessions (Murphy et al., 2010) . Third, we need to consider the potential effect size for those allocated to and compliant with an allocated aftercare intervention. A recent systematic review estimated that the absolute risk reduction for any repeat self-harm for all psychosocial interventions combined was 2.5% (18.0% vs. 20.5%). Even when this estimate was restricted to the most effective intervention (five cognitive behavioral therapy [CBT] studies), the absolute risk reduction was 9.9% (31.2% vs. 41.1%; Hetrick et al., 2016) . Even a 10% absolute reduction in repetition for the 7.6%-19.9% of patients allocated to the high-risk group in our studies would only increase the overall prevalence in repetition of self-harm by 1%-2%. We do not know of any randomized controlled trial that could be used to assess the accuracy of these estimates. However, a recent nonrandomized multicentre trial from eight EDs in the United States compared a universal screening plus intervention (secondary suicide risk screening by the ED physician, discharge resources, and post-ED telephone calls) to treatment as usual, with 1-year follow-up, a combined endpoint of any nonfatal suicide attempt or suicide death, with a reported prevalence rate for this endpoint of 20.9% (Miller, Camargo, & Arias, 2017) . Patients in the intervention phase showed a 5% absolute reduction in suicide attempt (23% vs. 18%) and about 8% (49% vs. 41%) for a wider combined suicidal behavior endpoint, which was less than the pooled estimate of 10% absolute reduction for the five CBT interventions. So confounding by indication, even with full treatment compliance, and the highest proven treatment response, would not improve the PPV sufficiently to be clinically useful.
Ultimately, however, it is important to understand that low prevalence outcomes impose a statistical ceiling on PPV (and a statistical limitation of LR+ values), which is independent of how the risk classification was made (Carter et al., 2017) .
Prediction and Prevalence
The use of clinician prediction for future clinical outcomes can be useful in some situations, although this is highly dependent on the prevalence (or pre-test probability) of the outcome being predicted. Low prevalence disorders impose a statistical ceiling on PPV and NPV, which means that prediction will not be accurate enough to be the basis on which to allocate or not allocate treatment to an individual patient. The ideal situation is for a pre-test probability of 50%, which means that statistically PPV and NPV might be clinically useful if the prediction (post-test probability) is accurate enough. A recent successful example of this approach has been in the clinician prediction of time to death in donor-eligible ICU patients (Brieva et al., 2014) .
However, prediction of future events like suicide cannot be adequately predicted because the event is of low prevalence (Rosen, 1954) ; in this study, we have shown that clinician prediction of future self-harm, which has a higher prevalence than suicide but is still a low prevalence behavior, is also not clinically useful for the allocation of after-care. In essence, clinician risk classification for future self-harm offers no meaningful improvement to the pre-test probability for any individual patient classified as high risk.
In order to achieve what we would consider to be the minimal threshold for a clinically useful level of accuracy based on likelihood ratios of LR+ 5.00 and LRÀ 0.1, we have calculated that for a pre-test probability of 14.4% and N = 22,499 patients, classification of high versus low risk would have the following properties: sensitivity 0.92, specificity 0.82, PPV 0.46, NPV 0.98, which would still result in the inappropriate 36 CLINICIAN PREDICTION OF SELF-HARM allocation of after-care intervention to 3,537 patients who would not be at risk of future self-harm and so could not benefit from that aspect of intervention, while failing to allocate after-care to 264 patients who would have future self-harm. Should this hypothetical level of test accuracy ever be achieved, nonallocation of after-care could be done accurately for 15,722 patients, and this would represent a substantial reduction in after-care costs compared to a system of allocation of after-care to all patients, with the additional "harm" of 264 (8%) future cases being misclassified as low risk and so not offered potentially beneficial after-care. However, we would conclude that the usual prevalence of future self-harm in hospital-treated self-harm populations (16%) and in psychiatric inpatient populations (6%) is simply too low to allow for clinically useful prediction in these two important hospital-treated populations.
Changing Current Practice
The NICE Clinical Guideline #133 in the UK recommends that risk assessment tools and scales to predict future suicide or repetition of self-harm should not be used as the basis to allocate after-care (NICE, 2011) , as does the Royal Australian and New Zealand College of Psychiatrists . Instead, recommendations are made for a needs-based approach combined with an assessment of modifiable risk factors to inform possible allocation of after-care on an individual patient basis (subject to agreement from the patient). We would endorse this approach for the allocation of after-care interventions. An excellent summary of the evidence base and potentially useful interventions has been proposed by the US Center for Disease Control (Stone et al., 2017) . After-care interventions for those discharged home should be aimed at meeting patient needs and by working with relevant community-based services (e.g., safety plans, personal support, resolution of interpersonal difficulties, social function, occupational function, vocational support, housing and financial needs); reducing exposure to modifiable clinical risk factors for self-harm and repeat self-harm (e.g., mental illness, substance misuse, personality disorder); and specific psychosocial therapies for reducing repetition of selfharm (Hetrick et al., 2016; National Health and Medical Research Council, 2012) .
In a review of UK general hospitals, guidelines for the assessment of needs were available for patients who self-harm in 7 of the 32 (21.7%) EDs and 29 of the 32 (90.6%) mental health services as part of the patients' wider assessment process (Quinlivan et al., 2014) . If this is a representative estimate of needs assessment at the national level in the UK, there is still considerable scope for improvement using this approach as the basis for allocation of after-care interventions, at least in the general hospital.
Little is known about how clinicians decide that a patient is not safe for discharge. The decision to transfer to a psychiatric hospital for continuing care after an episode of hospital-treated self-harm is associated with many factors; with higher levels of current suicide ideation and suicidal planning being the strongest independently associated variables (Carter, Safranko, Lewin, Whyte, & Bryant, 2006) . However, the appropriateness of this decision to transfer to and then admit to a psychiatric hospital cannot be determined; the effectiveness of psychiatric hospitalization to reduce future suicide and self-harm has never been tested in a randomized controlled trial. It is likely that changing the reliance by clinical services on risk classification to allocate after-care and to make the safe to discharge decisions will take some time, whether the outcome of interest is subsequent suicide or self-harm.
STRENGTHS AND LIMITATIONS
This study was based on a systematic search and review using the PRISMA standard. Quality ratings and risk of bias were conducted according to the QUADAS-2 standards, which is the appropriate instrument for studies of diagnostic precision or predicting future outcomes. Meta-analysis using appropriate models was conducted to produce pooled estimates of sensitivity, specificity, PPV, and NPV and to estimate between-study heterogeneity and potential publication bias. Clinical usefulness was comprehensively assessed by considering the sensitivity, specificity, PPV, NPV, LR+, LRÀ, CUI+, and CUIÀ values for individual evaluations. This is the first meta-analysis study of the accuracy of clinician prediction of future suicidal behaviours.
It is possible that our search missed some studies and it is possible that there may be a nonpublication bias for studies that failed to produce adequate prediction. The risk of bias in the selected evaluations was modest and the number of evaluations was also modest (eight evaluations on 22,499 occasions) and so the specific estimates must be viewed with a degree of caution. Future large-scale studies could potentially change the reported pooled estimates. The prevalence rates of future self-harm in the selected evaluations were similar; however, caution should be used in applying these result in populations with markedly different prevalence rates. Populations with lower prevalence rates will have even more dismal accuracy.
CONCLUSIONS
Simply stated, for clinician classification of high risk for repeated self-harm, the pooled sensitivity (0.31) indicates about 70% of repeater cases will be missed and the pooled PPV (0.22) indicates that a high-risk classification for repetition of selfharm will be incorrect nearly 80% of the time. This level of inaccuracy is just too high for this approach to be clinically useful to allocate or differentially allocate interventions to reduce the predicted outcome of repetition of self-harm. Clinician prediction of future self-harm is not adequately accurate to determine allocation of aftercare or safety to discharge. Given the low prevalence of future self-harm as an outcome, even in clinically high-risk populations, prediction by any method will not be clinically useful at the individual patient level. Instead we would recommend three approaches to allocation of clinical aftercare: (1) an individual needs-based assessment aimed at reducing exposure to modifiable risk factors Ryan & Large, 2013) ; (2) allocation of proven interventions for particular selected highrisk subpopulations, for example, those with borderline personality disorder (National Health and Medical Research Council, 2012) ; and (3) allocation of proven interventions that can be delivered to unselected high-risk clinical populations (Hetrick et al., 2016; Milner, Carter, Pirkis, Robinson, & Spittal, 2015) . There is currently no sufficiently accurate way to determine which patient is safe for discharge, whether the outcome of interest is suicide or selfharm.
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